Latest Cryolife (CRY) Headlines
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Mon Feb 24, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mpr3g/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures.This has further led to a rise in the demand for organ preservation solutions that help maintain the organs' viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher. Also, the American Society of Nephrology states that an aged patient's body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them. According to the U.S. Department of Health and Human Services, in 2011, 60% of the total number of individuals who underwent organ transplantation procedures in the U.S. were beyond 50 years of age. The global market for organ preservation solutions is expected to grow at a CAGR of 16.5% from 2013 to 2019 to reach an estimated value of USD 0.20 billion in 2019. The growth of this market will also be driven by the launch of technologically advanced products such as Lifor. Lifor is manufactured by Lifeblood Medical, Inc. and is currently utilized for research purposes only. It is also termed as a blood surrogate and once its effectiveness is clinically proven for preserving human and veterinary organs, the market for the same will grow significantly. Both the developed and developing countries have recorded growth in per capita healthcare expenditure which would provide people with less expensive and better healthcare services. This will also enable the patients to afford organ transplant procedures and hence the organ preservation solutions market will grow. However, growth of this market may get hampered due to high cost of transplantation procedures and lack of organ donors which may shift the preferences of surgeons towards artificial organs. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Recommendations - Company Profiles Companies Mentioned - 21st Century Medicine - BioLife Solutions - BioTime - Bristol-Myers Squibb - Claris Lifesciences - CryoLife - Dr. Franz K?hler Chemie - Lifeline Scientific - Teva Pharmaceutical Industries - ToleroTech - XVIVO Perfusion For more information visit http://www.researchandmarkets.com/research/5mpr3g/organ About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
NYSE stocks posting largest percentage decreases
AP - Thu Feb 20, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
Why CryoLife, Inc. Shares Have Gone Ice-Cold
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 12:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of CryoLife , a global human tissue...
CryoLife Fourth Quarter 2013 Revenues Increased 8 Percent to a Record $35.5 Million
PR Newswire - Thu Feb 20, 7:04AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2013. Revenues for the fourth quarter of 2013 increased 8 percent to a fourth quarter record of $35.5 million compared to $32.8 million for the fourth quarter of 2012. Revenues for the full year of 2013 increased 7 percent to a record $140.8 million compared to $131.7 million for the full year of 2012.
CryoLife's board approves USD0.0275 per share dividend for Q1 2014
M2 - Thu Feb 20, 4:14AM CST
The board of directors of CryoLife Inc (NYSE:CRY), a medical company, on Wednesday declared a dividend of USD0.0275 per share of its common stock outstanding for Q1 2014.
CryoLife, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:52PM CST
Pacific Coal Resources Ltd. (TSXV: PAK) announces the voluntary delisting of 74,749,976 warrants, being all of the Company's warrants currently trading on the TSX Venture Exchange under the symbol PAK.WT. Due to the minimal trading volume of the warrants, the Company is electing to delist the warrants to further its ongoing cost reduction initiative undertaken in 2012. The warrants are expected to be delisted at market close on March 18, 2013, being 20 trading days following the date of this release, as required by the TSXV.
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2014
PR Newswire - Wed Feb 19, 4:05PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2014 of $0.0275 per share of common stock outstanding. The quarterly cash dividend of $0.0275 per share will be paid on March 21, 2014 to all common stockholders of record as of March 14, 2014. The ex-dividend date for the quarterly dividend is March 12, 2014.
CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference
PR Newswire - Tue Feb 18, 3:52PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at The New York Palace Hotel in New York City.
CryoLife Announces Expansion in Asia Pacific Markets
PR Newswire - Tue Feb 18, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the establishment of CryoLife Asia Pacific Pte. Ltd., a wholly-owned subsidiary of CryoLife, Inc., to expand the Company's presence in the rapidly growing Asia Pacific medical device market. To support the new subsidiary, CryoLife will relocate Mr. Rich Gridley, vice president sales, Canada, Asia-Pacific, and The Americas, to a new regional headquarters in Singapore.
Implant Sciences Announces Order Valued at up to $1,500,000 in Latin America
PR Newswire - Thu Feb 13, 6:00AM CST
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences' fiscal year 2014 for deployment in Latin America.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CryoLife Announces Release Date and Teleconference Call Details for 2013 Fourth Quarter and Year End Financial Results
PR Newswire - Wed Feb 05, 8:09AM CST
CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 fourth quarter and year end financial results will be released on Thursday, February 20, 2014. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.
58.4% Return Seen to Date on SmarTrend CryoLife Call (CRY)
Comtex SmarTrend(R) - Tue Jan 28, 11:08AM CST
SmarTrend identified an Uptrend for CryoLife (NYSE:CRY) on September 20th, 2013 at $6.84. In approximately 4 months, CryoLife has returned 58.45% as of today's recent price of $10.83.
How To YieldBoost CryoLife From 1% To 9.8% Using Options
StockOptionsChannel.com - Tue Jan 28, 10:28AM CST
Shareholders of CryoLife, Inc. looking to boost their income beyond the stock's 1% annualized dividend yield can sell the July covered call at the $12.50 strike and collect the premium based on the 45 cents bid, which annualizes to an additional...
CryoLife Up 75.1% Since SmarTrend Uptrend Call (CRY)
Comtex SmarTrend(R) - Tue Jan 21, 9:43AM CST
SmarTrend identified an Uptrend for CryoLife (NYSE:CRY) on September 20th, 2013 at $6.84. In approximately 4 months, CryoLife has returned 75.13% as of today's recent price of $11.97.
Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:21AM CST
Pacific Biosciences of California, Inc. (PACB) was a big mover last session, as the company saw its shares rise by over 14% on the day.
Intuitive Surgical Expects Lower Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 4:50PM CST
ISRG shares fell 1.7% after the market closed yesterday.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Mon Feb 24, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mpr3g/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures.This has further led to a rise in the demand for organ preservation solutions that help maintain the organs' viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher. Also, the American Society of Nephrology states that an aged patient's body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them. According to the U.S. Department of Health and Human Services, in 2011, 60% of the total number of individuals who underwent organ transplantation procedures in the U.S. were beyond 50 years of age. The global market for organ preservation solutions is expected to grow at a CAGR of 16.5% from 2013 to 2019 to reach an estimated value of USD 0.20 billion in 2019. The growth of this market will also be driven by the launch of technologically advanced products such as Lifor. Lifor is manufactured by Lifeblood Medical, Inc. and is currently utilized for research purposes only. It is also termed as a blood surrogate and once its effectiveness is clinically proven for preserving human and veterinary organs, the market for the same will grow significantly. Both the developed and developing countries have recorded growth in per capita healthcare expenditure which would provide people with less expensive and better healthcare services. This will also enable the patients to afford organ transplant procedures and hence the organ preservation solutions market will grow. However, growth of this market may get hampered due to high cost of transplantation procedures and lack of organ donors which may shift the preferences of surgeons towards artificial organs. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Recommendations - Company Profiles Companies Mentioned - 21st Century Medicine - BioLife Solutions - BioTime - Bristol-Myers Squibb - Claris Lifesciences - CryoLife - Dr. Franz K?hler Chemie - Lifeline Scientific - Teva Pharmaceutical Industries - ToleroTech - XVIVO Perfusion For more information visit http://www.researchandmarkets.com/research/5mpr3g/organ About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
NYSE stocks posting largest percentage decreases
AP - Thu Feb 20, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
Why CryoLife, Inc. Shares Have Gone Ice-Cold
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 12:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of CryoLife , a global human tissue...
CryoLife Fourth Quarter 2013 Revenues Increased 8 Percent to a Record $35.5 Million
PR Newswire - Thu Feb 20, 7:04AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2013. Revenues for the fourth quarter of 2013 increased 8 percent to a fourth quarter record of $35.5 million compared to $32.8 million for the fourth quarter of 2012. Revenues for the full year of 2013 increased 7 percent to a record $140.8 million compared to $131.7 million for the full year of 2012.
CryoLife's board approves USD0.0275 per share dividend for Q1 2014
M2 - Thu Feb 20, 4:14AM CST
The board of directors of CryoLife Inc (NYSE:CRY), a medical company, on Wednesday declared a dividend of USD0.0275 per share of its common stock outstanding for Q1 2014.
CryoLife, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:52PM CST
Pacific Coal Resources Ltd. (TSXV: PAK) announces the voluntary delisting of 74,749,976 warrants, being all of the Company's warrants currently trading on the TSX Venture Exchange under the symbol PAK.WT. Due to the minimal trading volume of the warrants, the Company is electing to delist the warrants to further its ongoing cost reduction initiative undertaken in 2012. The warrants are expected to be delisted at market close on March 18, 2013, being 20 trading days following the date of this release, as required by the TSXV.
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2014
PR Newswire - Wed Feb 19, 4:05PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2014 of $0.0275 per share of common stock outstanding. The quarterly cash dividend of $0.0275 per share will be paid on March 21, 2014 to all common stockholders of record as of March 14, 2014. The ex-dividend date for the quarterly dividend is March 12, 2014.
CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference
PR Newswire - Tue Feb 18, 3:52PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at The New York Palace Hotel in New York City.
CryoLife Announces Expansion in Asia Pacific Markets
PR Newswire - Tue Feb 18, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the establishment of CryoLife Asia Pacific Pte. Ltd., a wholly-owned subsidiary of CryoLife, Inc., to expand the Company's presence in the rapidly growing Asia Pacific medical device market. To support the new subsidiary, CryoLife will relocate Mr. Rich Gridley, vice president sales, Canada, Asia-Pacific, and The Americas, to a new regional headquarters in Singapore.
Implant Sciences Announces Order Valued at up to $1,500,000 in Latin America
PR Newswire - Thu Feb 13, 6:00AM CST
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences' fiscal year 2014 for deployment in Latin America.
Global Biomaterials Market 2012-2016: High R&D Costs Could Pose a Challenge to the Growth of the Market
M2 - Wed Feb 05, 10:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/kl58bq/global) has announced the addition of the "Global Biomaterials Market 2012-2016" report to their offering. The analysts forecast the Global Biomaterials market to grow at a CAGR of 14.85 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Biomaterials market has also been witnessing the emergence of innovative biomaterial products. However, high R&D costs could pose a challenge to the growth of this market. The key vendors dominating this space include Biomet Inc., Evonik Industries AG, Exactech Inc., and Wright Medical Group Inc. The other vendors mentioned in this report are 3DM Inc., AdvanSource Biomaterials Corp., Allergan Inc., Alphatec Spine Inc., Amedica Corp., Angiotech Pharmaceuticals Inc., Basf SE, Bayer AG, Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioSyntech Inc., Cam Bioceramics BV, Carpenter Technology Corp., Ceradyne Inc., Ceramtec Collagen Matrix Inc., CollPlant Holdings Ltd., Covalon Technologies Ltd., CryoLife Inc., Dentsply International Inc., Depuy Orthopaedics Inc., Dsm Biomedical Inc., ETEX Corp., Heraeus Medical Components Inc., Hycail Finland OY, Integra LifeSciences Holdings Corp., Invibio Ltd., Kyocera Corp., Landec Corp., Materion Corp., Medtronic Inc., Morgan Technical Ceramics, Orthovita Inc., Osteotech Inc., Purac Biomaterials, RTI Biologics Inc., Sigma-Aldrich Corp., Starch Medical Inc., Stryker Corp., Ticona GmbH, Ulbrich Stainless Steels & Special Metals Inc., and Zimmer Holdings Inc. Commenting on the report, an analyst from the team said: There has been steady innovation in the Global Biomaterials market with several players increasing R&D expenditure every year. For instance, the use of carbon fiber in conjunction with biomaterials for the manufacture of composite materials is being explored. While innovation is imperative in an industry such as this where competition is rampant, the need for novel solutions to cater to patient needs in the Medical industry is also expected to lead to innovation in the market. Biomaterials were traditionally used for repair and replacement of body tissues. However, there has been an increasing focus on the provision of biomaterials for self-healing in patients. Thus, the Global Biomaterials market is expected to witness innovation. For more information visit http://www.researchandmarkets.com/research/kl58bq/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CryoLife Announces Release Date and Teleconference Call Details for 2013 Fourth Quarter and Year End Financial Results
PR Newswire - Wed Feb 05, 8:09AM CST
CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 fourth quarter and year end financial results will be released on Thursday, February 20, 2014. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.
58.4% Return Seen to Date on SmarTrend CryoLife Call (CRY)
Comtex SmarTrend(R) - Tue Jan 28, 11:08AM CST
SmarTrend identified an Uptrend for CryoLife (NYSE:CRY) on September 20th, 2013 at $6.84. In approximately 4 months, CryoLife has returned 58.45% as of today's recent price of $10.83.
How To YieldBoost CryoLife From 1% To 9.8% Using Options
StockOptionsChannel.com - Tue Jan 28, 10:28AM CST
Shareholders of CryoLife, Inc. looking to boost their income beyond the stock's 1% annualized dividend yield can sell the July covered call at the $12.50 strike and collect the premium based on the 45 cents bid, which annualizes to an additional...
CryoLife Up 75.1% Since SmarTrend Uptrend Call (CRY)
Comtex SmarTrend(R) - Tue Jan 21, 9:43AM CST
SmarTrend identified an Uptrend for CryoLife (NYSE:CRY) on September 20th, 2013 at $6.84. In approximately 4 months, CryoLife has returned 75.13% as of today's recent price of $11.97.
Pacific Biosciences of California (PACB) Surges: Stock Moves 14.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 8:21AM CST
Pacific Biosciences of California, Inc. (PACB) was a big mover last session, as the company saw its shares rise by over 14% on the day.
Intuitive Surgical Expects Lower Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 4:50PM CST
ISRG shares fell 1.7% after the market closed yesterday.
